Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced on November 10, 2026, that it intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ifetroban as a treatment for the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). This decision follows a pre-NDA meeting with the FDA this fall, during which the agency granted a rolling review of the application.
The submission will be supported by data from the Phase 2 FIGHT DMD trial. The data demonstrated a statistically significant improvement of 5.4 percentage points in left ventricular ejection fraction in the high-dose group compared to a control group of placebo-treated patients combined with propensity score-matched natural history patients. The company stated that ifetroban has maintained a favorable safety profile through up to 36 months of treatment, with no treatment-related serious adverse events reported.
The NDA will include long-term data from the ongoing open-label extension, preclinical data published in the Journal of the American Heart Association, manufacturing information, and a safety database of over 1,400 subjects across approximately 30 clinical studies. Ifetroban has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA, which has conditionally accepted the proprietary name DYSCORBAN for the product.
In addition to the DMD development, Cumberland reported top-line results from its Phase 2a ASSIST-SSc trial evaluating ifetroban in patients with Systemic Sclerosis. The company stated that ifetroban was generally well tolerated during the 12-month treatment period, with no serious adverse events assessed as related to the study drug.
Financially, the company reported net income of $77.8 million for the third quarter of 2026. This figure included a gain on the divestiture of assets related to a Strategic Transaction with Apotex Health, which closed on July 1, 2026. At September 30, 2026, Cumberland reported total assets of approximately $114 million, including $80.6 million in cash and cash equivalents. The company also announced a conference call for November 10, 2026, at 4:30 p.m. Eastern Time to discuss the results.
